Fear NOT!
By Bertalan Mesko, MD PhD
10 Reasons Why People Should Not Fear Digital Health Technologies
***
***
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
- PRACTICES: www.BusinessofMedicalPractice.com
- HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
- CLINICS: http://www.crcpress.com/product/isbn/9781439879900
- ADVISORS: www.CertifiedMedicalPlanner.org
- FINANCE: Financial Planning for Physicians and Advisors
- INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
- Dictionary of Health Economics and Finance
- Dictionary of Health Information Technology and Security
- Dictionary of Health Insurance and Managed Care

HEALTH INSURANCE, MANAGED CARE, ECONOMICS, FINANCE AND HEALTH INFORMATION TECHNOLOGY COMPANION DICTIONARY SET
Mike Stahl PhD MBA / Foreword Dr.Mata MD CIS / [Dr. Getzen PhD
***
Filed under: Experts Invited, Information Technology | Tagged: Bertalan Meskó, health information technolgy, HIT, IT, MD PhD |



















Med-Technology
Chilling and very cool.
RN
LikeLike
Digital therapeutics
“Digital therapeutics are at the forefront of a new era in healthcare, As the entire industry prepares for what’s next, we are excited to represent digital therapeutics in this rapidly evolving environment, working with regulators, patient advocacy groups, providers, payers and manufacturers.”
Pierre Leurent
[CEO, Voluntis]
LikeLike
Digital Pharma
“I think a lot of folks in pharma marketing now are being given a directive from above to increase the use of digital within their marketing programs and specifically in mHealth and wearable devices, which is a very hot and popular topic right now, but doing it just for the sake of doing it will not have the impact that pharma’s looking to have. Designing programs around patients who are interested in monitoring their conditions and figuring out their unmet needs will have that impact.”
Jeremy Brody
Executive VP, Corporate Development
Kantar Health
LikeLike